Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Forecast Reaching $8.59 Billion By 2030 At 22% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Projected To Reach By 2030?
The metabolic dysfunction-associated steatohepatitis (mash) treatment market size has experienced a significant surge in recent years. This market is projected to expand from $3.18 billion in 2025 to $3.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.2%. Historically, this growth can be ascribed to an escalating prevalence of obesity, a rising incidence of type 2 diabetes, increased public awareness of liver health disorders, the expansion of diagnostic testing capabilities, and the prompt adoption of lifestyle modification programs.
The metabolic dysfunction-associated steatohepatitis (mash) treatment market is projected to experience substantial growth in the upcoming years. It is anticipated to reach $8.6 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.0%. This expansion during the forecast period is largely driven by the rising uptake of GLP-1 agonists, advancements in antifibrotic drug development, the growing prevalence of digital liver monitoring tools, broader application of bariatric surgery, and an enhanced emphasis on tailored metabolic therapies. Key trends anticipated over the same period encompass the expansion of precision therapeutics for liver diseases, AI-powered early detection and risk stratification, cloud-based platforms for managing liver health data, IoT-integrated monitoring of lifestyle and medication, and the development of sustainable and preventive metabolic health initiatives.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
Which Factors Are Influencing The Growth Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The escalating rate of obesity is anticipated to drive expansion within the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the future. Obesity, a medical condition, involves an unhealthy buildup of body fat, detrimental to general well-being, commonly defined by a body mass index (BMI) of 30 or above. Globally, the incidence of obesity is on the rise, influenced by factors such as inactive lifestyles, poor dietary choices, and various metabolic risks. In the context of obesity, the approach to Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment centers on tackling insulin resistance, decreasing hepatic fat, and enhancing metabolic health via modifications in lifestyle and specific therapeutic interventions. As an illustration, figures from March 2023, reported by the World Heart Foundation, a non-governmental global cardiovascular organization located in Switzerland, indicate that around 2.3 billion adults and children globally are presently categorized as obese or overweight. Based on current obesity trends, this figure is forecast to climb to 2.7 billion by 2025. Consequently, the growing rate of obesity is fueling expansion in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
How Is The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Organized By Segment Classification?
The metabolic dysfunction-associated steatohepatitis (mash) treatment market covered in this report is segmented –
1) By Treatment: Drug, Therapy
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Which Trends Are Influencing Demand In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Major companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are prioritizing the creation of innovative products, such as liver fibrosis treatment solutions, to offer options for patients suffering from metabolic dysfunction-associated steatohepatitis (MASH) accompanied by moderate to severe liver fibrosis. These liver fibrosis treatments focus on addressing the fundamental causes of liver damage through lifestyle adjustments, antiviral medications, and advanced antifibrotic therapies, with the objective of halting or reversing fibrosis progression and enhancing liver function. As an example, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, declared the FDA approval of Rezdiffra (resmetirom), which is the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that demonstrated effectiveness in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This significant advancement provides a non-invasive treatment option, removing the need for liver biopsies, and substantially enhances patient access and outcomes in managing fatty liver disease.
Who Are The Industry Participants Involved In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA
Get The Full Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report:
Which Geographic Region Dominates The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2026, By The Business Research Company
Renal Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Cancer Biomarker Market Report
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Non Alcoholic Steatohepatitis Biomarkers Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
